ZTSMEDIUM SIGNALFINANCIAL10-K

Zoetis substantially increased share buybacks while undertaking significant balance sheet restructuring that reduced stockholders' equity by 30%.

The company's aggressive capital return strategy, with share buybacks increasing meaningfully year-over-year, signals management's confidence in cash generation but also contributed to a notable decline in stockholders' equity. The planned 2026 fiscal year alignment for international subsidiaries suggests operational streamlining efforts to improve reporting consistency and potentially enhance operational efficiency.

Comparing 2026-02-12 vs 2025-02-13View on EDGAR →
FINANCIAL ANALYSIS

Zoetis executed an aggressive capital return program with substantially higher share buybacks, while simultaneously restructuring its balance sheet as evidenced by a 28% increase in total liabilities and a 30% reduction in stockholders' equity. The company strengthened its working capital position with current assets growing 13% and current liabilities declining 35%, alongside a 21% increase in accounts receivable. This financial profile suggests active balance sheet management focused on returning capital to shareholders while maintaining operational liquidity.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+74.1%
$1.9B$3.2B

Share repurchases increased 74.1% — management returning capital, signals confidence in intrinsic value.

Current Liabilities
Balance Sheet
-34.5%
$3.4B$2.2B

Current liabilities reduced — improved short-term financial position and working capital health.

Stockholders Equity
Balance Sheet
-30.2%
$4.8B$3.3B

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Liabilities
Balance Sheet
+28.2%
$9.5B$12.1B

Liabilities increased 28.2% — monitor debt-to-equity ratio and interest coverage.

Accounts Receivable
Balance Sheet
+20.8%
$1.3B$1.6B

Receivables grew 20.8% — monitor days sales outstanding for collection efficiency.

Current Assets
Balance Sheet
+13.1%
$6.0B$6.8B

Current assets grew 13.1% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-02-12
PRIOR — 2025-02-13
ADDED
With a legacy of nearly 75 years, we continue to pioneer ways to predict, prevent, detect, and treat animal illness, supporting those raising and caring for animals worldwide - from veterinarians and pet owners to livestock producers.
As a result of these differences, among other things, we organize and operate our business in two segments: United States (U.S.) with revenue of $5,097 million, or 54% of total revenue for the year ended December 31, 2025; and International with revenue of $4,254 million, or 45% of total revenue for the year ended December 31, 2025.
In 2026, we expect to eliminate the one-month lag in reporting of our subsidiaries operating outside the U.S.
and align the fiscal years of the subsidiaries within our U.S.
segment and the subsidiaries within our International segment.
+7 more — sign up free →
REMOVED
For over 70 years, we have been innovating ways to predict, prevent, detect, and treat animal illness, and continue to stand by those raising and caring for animals worldwide - from veterinarians and pet owners to livestock producers.
As a result of these differences, among other things, we organize and operate our business in two segments: United States (U.S.) with revenue of $5,074 million, or 55% of total revenue for the year ended December 31, 2024; and International with revenue of $4,102 million, or 44% of total revenue for the year ended December 31, 2024.
Companion animal products represented approximately 68% of our revenue for the year ended December 31, 2024.
Livestock products represented approximately 31% of our revenue for the year ended December 31, 2024.
For example, the first product in our ceftiofur line was an anti-infective approved for treating bovine respiratory disease (BRD) in cattle that was administered via intramuscular injection.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →